Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 4,802 shares at $241.68 ($1.2M) on 2025-03-04, disclosed to the SEC on 2025-03-05.
Scheduled sale ($1.2M) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $242.37 | 204 | $49K | 4.2% |
| 2 | $242.69 | 465 | $113K | 9.7% |
| 3 | $242.69 | 465 | $113K | 9.7% |
| 4 | $243.36 | 224 | $55K | 4.7% |
| 5 | $243.36 | 224 | $55K | 4.7% |
| 6 | $243.94 | 487 |
| $119K |
| 10.2% |
| 7 | $243.94 | 487 | $119K | 10.2% |
| 8 | $244.41 | 151 | $37K | 3.2% |
| 9 | $245.26 | 111 | $27K | 2.3% |
| 10 | $245.30 | 219 | $54K | 4.6% |
| 11 | $245.30 | 219 | $54K | 4.6% |
| 12 | $246.18 | 45 | $11K | 0.9% |
| 13 | $247.35 | 4 | $989 | 0.1% |
| 14 | $248.36 | 1 | $248 | 0.0% |
| 15 | $239.24 | 121 | $29K | 2.5% |
| 16 | $240.95 | 328 | $79K | 6.8% |
| 17 | $240.95 | 328 | $79K | 6.8% |
| 18 | $241.68 | 324 | $78K | 6.7% |
| 19 | $241.68 | 324 | $78K | 6.7% |
| 20 | $242.93 | 71 | $17K | 1.5% |
| Total | $242.92 avg | 4,802 | $1.2M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |